Better Vaccines Faster
Vaccine manufacturers face a dilemma when it comes to rapidly evolving pathogens like SARS-CoV-2. What is the ‘right’ vaccine antigen profile? With Boost, you can have confidence that when a pathogen evolves, so does your vaccine.
Using Boost’s Rapid Antigen Deployment (RAD) Process, we create antigen frameworks and families that are quickly updatable to address new pathogenic strains – within ~14 days. Boost’s antigens are multimeric protein subunits that are highly expressed and easily purified using commonly available systems.
Our proprietary sequences also have the potential to avoid immune imprinting and antibody-dependent enhancement in certain instances. Boost is applying the RAD Process to create new vaccines for several important viral pathogens, including SARS-CoV-2 (we have created vaccine antigens for all variants of concern to date) and multiple Flaviviruses and other pathogens of global importance.
We are on a mission to extend the use of our RAD Process to create safe and effective vaccines for a wide range of global health threats that impact billions of lives.
Exceptional Antibodies
Boost uses its RAD Process and resulting potent antigens with unique combinatorial mutational profiles to generate exceptional monoclonal antibodies.
Boost’s SARS-CoV-2 mAb binds to a conserved region of the receptor binding domain (RBD), with neutralization across all tested strains of the virus, including recent variants of concern. The mAb appears to bind more tightly as the virus mutates.
Uses for Boost’s SARS-CoV-2 monoclonal antibody may include COVID-19 pre-exposure prophylaxis and treatment. Based on the literature, we believe that Boost’s SARS-CoV-2 monoclonal antibody could possibly also be useful as a therapy for long-COVID.
